Ichnos Glenmark Innovation

Early data on Ichnos Glenmark Innovation’s (IGI) trispecific T-cell engager ISB 2001 in multiple myeloma presented at the American Society of Clinical Oncology (ASCO) meeting has signalled “deep and d

These are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabili

Ichnos Glenmark Innovation (IGI) has a lot at stake as it readies to present first-time data from the Phase I study of its T cell-engaging trispecific antibody (ISB 2001) at the upcoming American Soci

Glenmark Pharmaceuticals Limited ’s revenue mix by region appears set for an overhaul, with Europe expected to match the US, a market where the Indian firm has been struggling to regain momentum. At t